Evaluating treatments for open-angle glaucoma in diverse patient populations
Official title: Designing a Pragmatic Registry-based Randomized Controlled Trial for Open-Angle Glaucoma Treatment in the US
Funded at University of California, San Francisco · NIH-10867985 · Data updated 2026-11-12
This study is looking at how well a special laser treatment works compared to eye drops for people with open-angle glaucoma, and it's open to a diverse group of patients to make sure the results reflect everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $491,429 |
| NIH project number | 1R34EY036161-01 |
| Project ID | NIH-10867985 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have recently been diagnosed with open-angle glaucoma and represent a variety of racial, ethnic, and socioeconomic backgrounds.
✕Less likely to help
Patients who do not have open-angle glaucoma or those who have advanced glaucoma requiring immediate intervention may not benefit from this research.
What this research studies
This research aims to investigate the effectiveness of selective laser trabeculoplasty (SLT) compared to medications for treating open-angle glaucoma in a diverse group of patients. By utilizing a pragmatic registry-based randomized controlled trial approach, the study seeks to recruit participants from various racial and ethnic backgrounds, as well as those with different levels of English proficiency and health insurance status. This method allows for a more accurate representation of the US population and aims to provide high-quality evidence on treatment efficacy in real-world settings. The study will focus on patients who have recently been diagnosed with open-angle glaucoma and may have other eye conditions.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for open-angle glaucoma that are effective across diverse populations.
How similar studies have gone: Previous research has shown that pragmatic registry-based trials can effectively recruit diverse populations and yield valuable insights, indicating a promising approach for this study.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Sun, Catherine Qing — University of California, San Francisco
- Study coordinator: Sun, Catherine Qing
Related research
Other NIH-funded projects on the same topics.
-
Artificial Intelligence–Assisted Teleophthalmology for Glaucoma Screening
A large trial tests an AI-powered teleophthalmology platform to screen for glaucoma and help guide care, with patients at risk of vision loss in mind.
-
Gene therapy to normalize eye pressure in juvenile glaucoma
A first-in-class gene therapy using a safe viral vector is being explored to normalize eye pressure in children and adults with juvenile open-angle glaucoma.
-
Improving glaucoma risk predictions using diverse genetic data
A glaucoma study uses genetic data from people of African, American, and European ancestry to build better risk scores and help with early detection.
-
Multimodal AI to predict glaucoma progression and guide care
A big-data AI tool uses eye images, scans, field tests, and health info to help predict who with open-angle glaucoma is at higher risk of vision loss so doctors can act sooner.
-
Repairing the eye's drainage support to lower pressure in steroid-related and open-angle glaucoma
This work tests whether reversing changes in the support tissue around drainage cells can help lower eye pressure for people with steroid-induced high eye pressure and open-angle glaucoma.
-
Replacing damaged eye drainage cells to treat glaucoma
This project is developing a cell-based treatment to replace lost drainage cells and help people with primary open-angle glaucoma keep eye pressure lower and protect vision.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.